Literature DB >> 8386261

Resistance of herpes simplex virus type 2 to neomycin maps to the N-terminal portion of glycoprotein C.

A M Oyan1, K E Dolter, N Langeland, W F Goins, J C Glorioso, L Haarr, C S Crumpacker.   

Abstract

Entry of herpes simplex virus (HSV) into cells is believed to be mediated by specific binding of envelope proteins to a cellular receptor. Neomycin specifically blocks this initial step in infection by HSV-1 but not HSV-2. Resistance of HSV-2 to this compound maps to a region of the genome encoding glycoprotein C (gC-2). We have studied the function of gC-2 in the initial interaction of the virus with the host cell, using HSV-2 mutants deleted for gC-2 and gC-2-rescued recombinants. Resistance to neomycin was directly linked to the presence of gC-2 within the viral genome. In addition, deletion of the gC-2 gene caused a marked delay in adsorption to cells relative to the wild-type virus. HSV-1 recombinants containing chimeric gC genes composed of HSV-1 and HSV-2 sequences were used to localize neomycin resistance within the N-terminal 223 amino acids of gC-2. This region of the glycoprotein comprises an important domain responsible for binding of HSV-2 to cell receptors in the presence of neomycin. A gC-2-negative mutant is still infectious, indicating that HSV-2 also has an alternative pathway of adsorption.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8386261      PMCID: PMC237561     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  41 in total

1.  Transfection of human lymphoblastoid cells with herpes simplex viral DNA.

Authors:  G Miller; P Wertheim; G Wilson; J Robinson; J L Geelen; J van der Noordaa; A J van der Eb
Journal:  Proc Natl Acad Sci U S A       Date:  1979-02       Impact factor: 11.205

2.  The gIII glycoprotein of pseudorabies virus is involved in two distinct steps of virus attachment.

Authors:  L Zsak; N Sugg; T Ben-Porat; A K Robbins; M E Whealy; L W Enquist
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

3.  The HSV-1 UL45 gene product is not required for growth in Vero cells.

Authors:  R J Visalli; C R Brandt
Journal:  Virology       Date:  1991-11       Impact factor: 3.616

4.  Polyoma transformation of hamster cell clones--an investigation of genetic factors affecting cell competence.

Authors:  I MACPHERSON; M STOKER
Journal:  Virology       Date:  1962-02       Impact factor: 3.616

5.  Genetic studies with herpes simplex virus type 1. The isolation of temperature-sensitive mutants, their arrangement into complementation groups and recombination analysis leading to a linkage map.

Authors:  S M Brown; D A Ritchie; J H Subak-Sharpe
Journal:  J Gen Virol       Date:  1973-03       Impact factor: 3.891

6.  Temperature-sensitive mutants of herpes simplex virus type 2.

Authors:  M C Timbury
Journal:  J Gen Virol       Date:  1971-11       Impact factor: 3.891

7.  Genetic analysis of type-specific antigenic determinants of herpes simplex virus glycoprotein C.

Authors:  K E Dolter; W F Goins; M Levine; J C Glorioso
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

8.  Neomycin is a platelet-derived growth factor (PDGF) antagonist that allows discrimination of PDGF alpha- and beta-receptor signals in cells expressing both receptor types.

Authors:  F S Vassbotn; A Ostman; A Siegbahn; H Holmsen; C H Heldin
Journal:  J Biol Chem       Date:  1992-08-05       Impact factor: 5.157

9.  A human cytomegalovirus glycoprotein complex designated gC-II is a major heparin-binding component of the envelope.

Authors:  B Kari; R Gehrz
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

10.  Cell surface receptors for herpes simplex virus are heparan sulfate proteoglycans.

Authors:  M T Shieh; D WuDunn; R I Montgomery; J D Esko; P G Spear
Journal:  J Cell Biol       Date:  1992-03       Impact factor: 10.539

View more
  9 in total

1.  Inhibition of herpes simplex virus type 1 and type 2 infections by peptide-derivatized dendrimers.

Authors:  Anna Luganini; Silvia Fabiole Nicoletto; Lorena Pizzuto; Giovanna Pirri; Andrea Giuliani; Santo Landolfo; Giorgio Gribaudo
Journal:  Antimicrob Agents Chemother       Date:  2011-05-16       Impact factor: 5.191

2.  Equine herpesvirus type 1-mediated oncolysis of human glioblastoma multiforme cells.

Authors:  Michael J Courchesne; Maria C White; Brent A Stanfield; Arthur R Frampton
Journal:  J Virol       Date:  2011-12-28       Impact factor: 5.103

3.  A heterologous heparin-binding domain can promote functional attachment of a pseudorabies virus gC mutant to cell surfaces.

Authors:  S J Flynn; P Ryan
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

4.  Evidence for a multistep mechanism for cell-cell fusion by herpes simplex virus with mutations in the syn 3 locus using heparin derivatives during fusion from within.

Authors:  T Seck; M Lingen; K Weise; D Falke
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

5.  Herpes simplex virus types 1 and 2 differ in their interaction with heparan sulfate.

Authors:  E Trybala; J A Liljeqvist; B Svennerholm; T Bergström
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

6.  Dextran sulfate can act as an artificial receptor to mediate a type-specific herpes simplex virus infection via glycoprotein B.

Authors:  A P Dyer; B W Banfield; D Martindale; D M Spannier; F Tufaro
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

7.  Differences in the susceptibility of herpes simplex virus types 1 and 2 to modified heparin compounds suggest serotype differences in viral entry.

Authors:  B C Herold; S I Gerber; B J Belval; A M Siston; N Shulman
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

8.  Herpes simplex virus type 2 glycoprotein G is targeted by the sulfated oligo- and polysaccharide inhibitors of virus attachment to cells.

Authors:  Beata Adamiak; Maria Ekblad; Tomas Bergström; Vito Ferro; Edward Trybala
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

9.  Inhibition of herpes simplex virus types 1 and 2 in vitro infection by sulfated derivatives of Escherichia coli K5 polysaccharide.

Authors:  Debora Pinna; Pasqua Oreste; Tiziana Coradin; Anna Kajaste-Rudnitski; Silvia Ghezzi; Giorgio Zoppetti; Antonella Rotola; Rafaela Argnani; Guido Poli; Roberto Manservigi; Elisa Vicenzi
Journal:  Antimicrob Agents Chemother       Date:  2008-06-23       Impact factor: 5.191

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.